First Financial Bank Trust Division Makes New Investment in Capricor Therapeutics, Inc. $CAPR

First Financial Bank Trust Division acquired a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 28,089 shares of the biotechnology company’s stock, valued at approximately $203,000. First Financial Bank Trust Division owned approximately 0.06% of Capricor Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the last quarter. KLP Kapitalforvaltning AS increased its holdings in shares of Capricor Therapeutics by 65.2% in the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after buying an additional 4,300 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Capricor Therapeutics in the second quarter worth about $135,000. Stoneridge Investment Partners LLC bought a new stake in shares of Capricor Therapeutics in the 1st quarter valued at about $150,000. Finally, Worth Venture Partners LLC purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $155,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 4.3%

NASDAQ:CAPR opened at $26.02 on Monday. The firm’s fifty day simple moving average is $9.59 and its 200 day simple moving average is $8.82. The stock has a market cap of $1.19 billion, a P/E ratio of -14.46 and a beta of 0.62. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). On average, analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Roth Capital lifted their price target on Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (up previously from $20.00) on shares of Capricor Therapeutics in a report on Wednesday. Maxim Group upped their price target on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Finally, Industrial Alliance Securities set a $48.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.00.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.